echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > AstraZenecon's long-acting new coronary antibody begins phase III clinically.

    AstraZenecon's long-acting new coronary antibody begins phase III clinically.

    • Last Update: 2020-10-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today AstraZenecom announced that its long-acting new coronary antibody (LAAB) combination will begin a phase III clinical trial of prevention for 6,000 people and a Phase III clinical trial for 4,000 people.
    the drug, codenamed AZD7442, is a mixture of two antibodies called COV2-2196 and COV2-2130, which bind to two different bits of the new coronary S protein.
    AZN's acquisition of Vanderbilt University in June to extend its half-life with its own Fc modifications.
    AZN received $460 million from the U.S. government to fund the development of the project, the third U.S. government-backed antibody drug, which the government has promised will be available free of charge if it available as a preventive drug.
    AZN will provide 100,000 AZD7442s this year and 1 million next year under the agreement.
    new crown in the world's pandemic has called for large and small pharmaceutical called to this once-in-a-century health crisis.
    phase III clinical studies, redsivir and hydroxychloroquine, were first conducted through cell screening of older drugs.
    neJM published the latest Phase III clinical results of both drugs yesterday.
    although the activity of the two is almost the same in cellular experiments, but the clinical effect is different.
    redsiwe showed that hospital stays could be reduced but not the four-week mortality rate, while hydroxychloroquine was ineffective.
    jak inhibitors and Redsiwe can further reduce hospital stays.
    of course Redsiway also failed in a previous phase III clinical failure, while hydroxychloroquine failed in multiple therapeutic phase III.
    the three good students in the first grade of these two elementary schools did not grow up to meet the expectations of the time, shorter hospital stays, although also an achievement, but the world panicked about the death rate.
    the only thing that now shows survival advantage is the steroid hormone steroid dexamisone, but the drug does not reduce viral load and is only effective in severely ill patients.
    is best for early-stage patients with mild illness to reduce viral load as quickly as possible and avoid became severe.
    is suitable for people with mild illness, as a direct antiviral drug does not reduce viral load, it is suspected that its working mechanism has antiviral components.
    Lilly and Regenerative Have recently published phase II clinical results of the new coronary antibody and antibody mixture, which, although not ideal for tissue distribution, show strong virus removal efficacy due to directly meso-virus.
    especially the antibody mixtures REN-CoV2 and LY-CoV555, because they contain two antibodies binding to different bits of S-protein, it can more effectively avoid the escape of virus mutations, showing a more credible reduction of viral load efficacy.
    U.S. President Donald Trump's recent new crown and the use of REN-CoV2 appear to be getting better.
    but the effective dose of these antibodies is very high, at about 7-8 grams per 4 stitches.
    the half-life of a typical antibody for a few weeks may be enough for treatment, but as a precaution it is less convenient and too expensive.
    AZN, a long-acting antibody, may solve the problem to some extent, and is said to last 6-12 months, which may be longer than the vaccine's protection period.
    of course, long-acting drugs are not risk-free, and it is more difficult to reverse adverse reactions.
    because these antibodies should not be used for long-term safety experiments, there is still a risk if there are no reversal measures to use.
    Usually long-acting versions of the drug itself have gone through a long period of safe use without any problems before it is worth the risk, such as the six-month-old PCSK9 RNAi drug before already has antibodies to multiple large phase III clinical and post-market safety data support.
    that the new drug, which does not have large clinical safety data, has a half-year life and a half also shows the special circumstances of the new crown 100,000 urgent.
    two antibody modifications may also have another consideration, which is to avoid so-called antibody-mediated enhancement (ADE).
    side effects can also occur through Fc receptors, where cells may swallow antibodies that have been bind to the new crown.
    most cases these endo-swallowing antibodies and viruses degrade, but there are also individual cases in which host cells establish new bases for the virus.
    ADE is a concern for antibody and vaccine development, but there is no evidence that the phenomenon exists in the new crown.
    So retrofitting Fc not only prolongs the half-life (possibly increasing binding to antibody circulating Fc receptors through amino acid variation) but also reducing the risk of ADE binding to certain immune cell Fc receptors, although the former has its own risks and the latter can be worrying.
    () 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.